Should treatment of relapsed HCL be high-dose BRAF inhibitor and rituximab every 14 days for three months, followed by maintenance low-dose BRAF inhibitor and rituximab every 28 days for a total of one year? Should treatment of relapsed HCL be high-dose BRAF inhibitor and rituximab for one year? Here, BRAF is linked to hairy cell leukemia.